Patients Sue Genzyme Over Fabrazyme Rationing

Law360, New York (March 11, 2011, 1:57 PM EST) -- A group of patients slapped Genzyme Corp. with a putative national class action in Pennsylvania on Wednesday over the rationing plan it implemented for its enzyme replacement drug Fabrazyme after safety violations at its manufacturing plant forced it to cut production.

Matthew L. Kurzweg and C. Allen Black Jr. of Kurzweg Law Offices lodged the suit in the U.S. District Court for the Western District of Pennsylvania, alleging Genyzme's policy barring patients from receiving full recommended doses of Fabrazyme has caused them preventable and serious health...
To view the full article, register now.